ArticlePloS one2013

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Octavian Bucur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.